Metraipolis › archive › dc_dc247ff7c727

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis — Europe PMC PMID:41906525

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41906525
DOI
10.1111/ijd.70371
License (as archived)
solo-consultazione
Archived
2026-11-03T17:28:56.340Z
SHA-256 of the archived text
22b153f4ee2c6d7544212c973667f8db00474c1d93085dcd3782a86015c931af
Stable URL of this page
https://metraipolis.com/documento/dc_dc247ff7c727

How to cite

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis — Europe PMC PMID:41906525 — Europe PMC (en), https://europepmc.org/article/MED/41906525 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dc247ff7c727 (Metraipolis archive dc_dc247ff7c727, sha256 22b153f4ee2c6d7544212c973667f8db00474c1d93085dcd3782a86015c931af)
BibTeX
@misc{dcdc247ff7c727,
  title = {Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis — Europe PMC PMID:41906525},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41906525},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dc247ff7c727; sha256 22b153f4ee2c6d7544212c973667f8db00474c1d93085dcd3782a86015c931af},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41906525. Agents can read the archived copy with the MCP tool read_document.